Palivizumab
Based on 3 publication(s) in Google Scholar
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice.
For research use only. We do not sell to patients.
- Purity : 99.63%
- CAS No.: 188039-54-5
- Molecular Weight:145.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99756
NirsevimabAnti-RSV Antibody -
HY-P99209
MotavizumabAnti-RSV mAb -
HY-P99804
ClesrovimabAnti-RSV Monoclonal Antibody -
HY-B0434
RibavirinAntiviral Agent -
HY-123475
SisunatovirRSV-F Protein Inhibitor -
HY-16727
PresatovirRSV Fusion Inhibitor -
HY-102038
PC786RSV Inhibitor -
HY-11097
TMC353121RSV Inhibitor -
HY-12983
ALS-8112 -
HY-P9907
TrastuzumabHER2 Blocking Antibody -
HY-123475A
Sisunatovir hydrochlorideRSV-F Protein Inhibitor -
HY-P9917
TocilizumabIL-6R Neutralizing Antibody
Publications Citing Use of MedChemExpress (MCE) Palivizumab
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
RSV-F
In Vitro
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The cotton rat model of RSV infection[1].
-
Dosage:0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.)
-
Administration:Intramuscular injection (i.m.) or intravenous injection (i.v.); single dose
-
Result:Reduced virus replication and did not cause RSV infection or pathological increase in both initial and secondary attacks.
-
Animal Model:BALB/c mice[2].
-
Dosage:0.05 mg/kg
-
Administration:Intranasally administered; single dose
-
Result:Reduced the RSV load.
-
Animal Model:Capsaicin-induced neurogenic inflammation in the airways of rats[3].
-
Dosage:15 mg/kg
-
Administration:Subcutaneous injection (s.c.); single dose
-
Result:Reduced neurogenic extravasation and neurogenic inflammation.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
A0A0X8XRK2
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human respiratory syncytial virus (RSV) Prefusion glycoprotein F can bind Palivizumab. The EC50 for this effect is 2.043 ng/mL.
Chemical Information
-
CAS No. 188039-54-5
-
Appearance Liquid
-
Molecular Weight 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Palivizumab]
-
Synonyms
MEDI 493
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
An oral vaccine based on the Ad5 vector with a double-stranded RNA adjuvant protects mice against respiratory syncytial virus. [Abstract]2025 Jan 27:146:113970. PMID: 39736241 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Npj Viruses
STAT1 signaling controls cholesterol metabolism in epithelial cells and RSV-induced syncytia formation. [Abstract]2026 Feb 16;4(1):10. PMID: 41699197
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24. [Content Brief]
[2]. Jacobino SR, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018 Apr;10(3):453-462. [Content Brief]
[3]. Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res. 2000 Mar;47(3):351-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Palivizumab Related Classifications
HY-P9944 Related Classifications
Powered by Bioz